BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 9516864)

  • 1. The International Neuroblastoma Risk Groups (INRG): a preliminary report.
    Castleberry RP; Pritchard J; Ambros P; Berthold F; Brodeur GM; Castel V; Cohn SL; De Bernardi B; Dicks-Mireaux C; Frappaz D; Haase GM; Haber M; Jones DR; Joshi VV; Kaneko M; Kemshead JT; Kogner P; Lee RE; Matthay KK; Michon JM; Monclair R; Roald BR; Seeger RC; Shaw PJ; Shuster JJ
    Eur J Cancer; 1997 Oct; 33(12):2113-6. PubMed ID: 9516864
    [No Abstract]   [Full Text] [Related]  

  • 2. The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report.
    Monclair T; Brodeur GM; Ambros PF; Brisse HJ; Cecchetto G; Holmes K; Kaneko M; London WB; Matthay KK; Nuchtern JG; von Schweinitz D; Simon T; Cohn SL; Pearson AD;
    J Clin Oncol; 2009 Jan; 27(2):298-303. PubMed ID: 19047290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Surgical management in pediatric neuroblastoma diagnosis and treatment: a 20-year, single-center experience.
    Spencer B; Patel A; Cilley R; Grant CN
    World J Pediatr; 2022 Feb; 18(2):120-125. PubMed ID: 34854024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The current contribution of molecular factors to risk estimation in neuroblastoma patients.
    Berthold F; Sahin K; Hero B; Christiansen H; Gehring M; Harms D; Horz S; Lampert F; Schwab M; Terpe J
    Eur J Cancer; 1997 Oct; 33(12):2092-7. PubMed ID: 9516860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complete surgical resection improves outcome in INRG high-risk patients with localized neuroblastoma older than 18 months.
    Fischer J; Pohl A; Volland R; Hero B; Dübbers M; Cernaianu G; Berthold F; von Schweinitz D; Simon T
    BMC Cancer; 2017 Aug; 17(1):520. PubMed ID: 28778185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A review of neuroblastoma image-defined risk factors on magnetic resonance imaging.
    Chen AM; Trout AT; Towbin AJ
    Pediatr Radiol; 2018 Aug; 48(9):1337-1347. PubMed ID: 30078048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Significance of clinical and biologic features in Stage 3 neuroblastoma: a report from the International Neuroblastoma Risk Group project.
    Meany HJ; London WB; Ambros PF; Matthay KK; Monclair T; Simon T; Garaventa A; Berthold F; Nakagawara A; Cohn SL; Pearson AD; Park JR
    Pediatr Blood Cancer; 2014 Nov; 61(11):1932-9. PubMed ID: 25044743
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuroblastoma: the impact of biology and cooperation leading to personalized treatments.
    Owens C; Irwin M
    Crit Rev Clin Lab Sci; 2012; 49(3):85-115. PubMed ID: 22646747
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surgical management and outcome of locoregional neuroblastoma: comparison of the Childrens Cancer Group and the international staging systems.
    Haase GM; Atkinson JB; Stram DO; Lukens JN; Matthay KK
    J Pediatr Surg; 1995 Feb; 30(2):289-94; discussion 295. PubMed ID: 7738753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bilateral adrenal neuroblastoma in the infant: Is it an image-defined risk factor?
    Marino S; La Spina M; Scuderi MG; Di Benedetto V; Magro G; Belfiore G; Coronella M; D'Amico S; Lo Nigro L; Russo G; Di Cataldo A
    Pediatr Hematol Oncol; 2016 May; 33(4):259-63. PubMed ID: 27285992
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genome-wide methylation profiling identifies novel methylated genes in neuroblastoma tumors.
    Olsson M; Beck S; Kogner P; Martinsson T; Carén H
    Epigenetics; 2016; 11(1):74-84. PubMed ID: 26786290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enlarged and prominent nucleoli may be indicative of MYCN amplification: a study of neuroblastoma (Schwannian stroma-poor), undifferentiated/poorly differentiated subtype with high mitosis-karyorrhexis index.
    Kobayashi C; Monforte-Munoz HL; Gerbing RB; Stram DO; Matthay KK; Lukens JN; Seeger RC; Shimada H
    Cancer; 2005 Jan; 103(1):174-80. PubMed ID: 15549714
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Practical Application of the International Neuroblastoma Risk Group Staging System: A Pictorial Review.
    Del Campo Braojos F; Donnelly LF
    Curr Probl Diagn Radiol; 2019; 48(5):509-518. PubMed ID: 30268582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of image-defined risk factors on the outcome of patients with localised neuroblastoma. A report from the LNESG1 study of the European International Society of Paediatric Oncology Neuroblastoma Group.
    Monclair T; Mosseri V; Cecchetto G; De Bernardi B; Michon J; Holmes K
    Pediatr Blood Cancer; 2015 Sep; 62(9):1536-42. PubMed ID: 25663103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is the prognosis of stage 4s neuroblastoma in patients 12 months of age and older really excellent?
    Iehara T; Hiyama E; Tajiri T; Yoneda A; Hamazaki M; Fukuzawa M; Hosoi H; Sugimoto T; Sawada T
    Eur J Cancer; 2012 Jul; 48(11):1707-12. PubMed ID: 22305511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tailoring Therapy for Children With Neuroblastoma on the Basis of Risk Group Classification: Past, Present, and Future.
    Liang WH; Federico SM; London WB; Naranjo A; Irwin MS; Volchenboum SL; Cohn SL
    JCO Clin Cancer Inform; 2020 Oct; 4():895-905. PubMed ID: 33058692
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [New international staging system and classification of risk groups in neuroblastoma].
    Balwierz W; Wieczorek A
    Przegl Lek; 2010; 67(6):345-9. PubMed ID: 21344759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MIBG avidity correlates with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group.
    DuBois SG; Mody R; Naranjo A; Van Ryn C; Russ D; Oldridge D; Kreissman S; Baker DL; Parisi M; Shulkin BL; Bai H; Diskin SJ; Batra V; Maris JM; Park JR; Matthay KK; Yanik G
    Pediatr Blood Cancer; 2017 Nov; 64(11):. PubMed ID: 28383813
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic impact of MYCN, DDX1, TrkA, and TrkC gene transcripts expression in neuroblastoma.
    de Souza DR; Sanabani SS; de Souza AC; Filho Odone V; Epelman S; Bendit I
    Pediatr Blood Cancer; 2011 May; 56(5):749-56. PubMed ID: 21154590
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proliferation marker KI-S5 discriminates between favorable and adverse prognosis in advanced stages of neuroblastoma with and without MYCN amplification.
    Krams M; Hero B; Berthold F; Parwaresch R; Harms D; Rudolph P
    Cancer; 2002 Feb; 94(3):854-61. PubMed ID: 11857322
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.